Bao Lei, Shi Yuan
Department of Neonatology, Children's Hospital of Chongqing Medical University/Ministry of Education Key Laboratory of Child Development and Disorders/China International Science and Technology Cooperation Base of Child Development and Critical Disorders/Chongqing Engineering Research Center of Stem Cell Therapy, Chongqing 400014, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2019 Jul;21(7):619-623. doi: 10.7499/j.issn.1008-8830.2019.07.001.
Bronchopulmonary dysplasia (BPD) is one of the most common chronic lung diseases in neonates especially in preterm infants. It is also the main reason leading to a poor prognosis. The prognosis of the neonates with BPD is unsatisfactory with current treatment strategies. Recent clinical trails have found that mesenchymal stem cell (MSC) transplantation might be effective and promising for treatment of BPD in neonates. This article outlines the characteristics of MSC and the potential mechanisms of MSC transplantation for BPD in vivo, and the safety and feasibility of MSC transplantation in BPD neonates, as well as the challenges in clinical trials on MSC transplantation for treatment of BPD.
支气管肺发育不良（BPD）是新生儿尤其是早产儿中最常见的慢性肺部疾病之一。它也是导致预后不良的主要原因。目前的治疗策略下，患有BPD的新生儿预后并不理想。最近的临床试验发现，间充质干细胞（MSC）移植可能对治疗新生儿BPD有效且具有前景。本文概述了MSC的特征、MSC移植治疗BPD的潜在体内机制、MSC移植在BPD新生儿中的安全性和可行性，以及MSC移植治疗BPD临床试验中的挑战。
